#### Tumor heterogeneity and immune-evasive T follicular cell lymphoma phenotypes at

#### single-cell resolution

Sakurako Suma<sup>1</sup>, Yasuhito Suehara<sup>1</sup>, Manabu Fujisawa<sup>2, 3</sup>, Yoshiaki Abe<sup>2</sup>, Keiichiro Hattori<sup>1, 2</sup>, Kenichi Makishima<sup>1</sup>, Tatsuhiro Sakamoto<sup>1, 2</sup>, Aya Sawa<sup>4</sup>, Hiroko Bando<sup>4</sup>, Daisuke Kaji<sup>5</sup>, Takeshi Sugio<sup>6</sup>, Koji Kato<sup>7</sup>, Koichi Akashi<sup>7</sup>, Kosei Matsue<sup>8</sup>, Joaquim Carreras<sup>9</sup>, Naoya Nakamura<sup>9</sup>, Ayako Suzuki<sup>10</sup>, Yutaka Suzuki<sup>10</sup>, Ken Ito<sup>11</sup>, Hiroyuki Shiiba<sup>12</sup>, Shigeru Chiba<sup>1, 2</sup>, and Mamiko Sakata-Yanagimoto<sup>1, 2, 13</sup>

<sup>1</sup> Department of Hematology, University of Tsukuba Hospital, Tsukuba, Japan.

<sup>2</sup> Department of Hematology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.

<sup>3</sup> Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.

<sup>4</sup> Department of Breast-Thyroid-Endocrine Surgery, University of Tsukuba Hospital, Tsukuba, Japan. <sup>5</sup> Department of Hematology, Toranomon Hospital, Tokyo, Japan.

<sup>6</sup> Department of Medicine, Division of Oncology, Stanford University, Stanford, CA, USA.

<sup>7</sup> Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Science, Fukuoka, Japan.

<sup>8</sup> Division of Hematology/Oncology, Department of Internal Medicine, Kameda Medical Center, Kamogawa, Japan.

<sup>9</sup> Department of Pathology, Tokai University School of Medicine, Isehara, Japan.

<sup>10</sup> Department of Computational Biology and Medical Sciences, the University of Tokyo, Kashiwa, Japan.
<sup>11</sup> Oncology Business Unit, Eisai Co., Ltd., Tsukuba, Japan.

<sup>12</sup> Oncology Department, Medical Head Quarters, Eisai Co., Ltd., Tokyo, Japan.

<sup>13</sup> Division of Advanced Hemato-Oncology, Transborder Medical Research Center, University of Tsukuba, Tsukuba, Japan.

Supplementary Methods

Supplementary Notes

Supplementary Table Legends

Supplementary Figures (with legends)

#### **1** Supplementary Methods

#### 2 Patients and clinical sample collection

3 Lymph node (LN) and peripheral blood (PB) samples were collected from 14 patients with 4 T follicular helper cell ( $T_{FH}$ ) lymphomas (TFHLs) at the University of Tsukuba Hospital, Kameda Medical Center (Kamogawa, Japan), and Toranomon Hospital (Tokyo, Japan) between October 5 6 of 2019 and February of 2021. For two of the TFHL patients (AITL1 and AITL2), PB samples 7 were collected at two-time points: once upon new diagnosis (ND) (AITL1<sub>ND</sub> and AITL2<sub>ND</sub>) and 8 again upon refractory/relapsed (RR) disease (AITL1<sub>RR</sub> and AITL2<sub>RR</sub>). LN samples from AITL5 9 and AITL7 were analyzed in a previously reported study [1]. For single-cell RNA sequencing 10 (scRNA-seq) data from AITL4, only tumor cells were analyzed because systemic steroid 11 administration for coexisting collagen disease may affect the composition of immune cells. 12 Additionally, seven homeostatic LN (HLN) samples were also collected from patients with non-13 hematological malignancies at the University of Tsukuba Hospital and were confirmed as 14 metastatic-free by flow cytometric (FCM) analysis of pan-cytokeratin. The patient characteristics 15 are summarized in Table S1.

16

#### 17 Sample processing

LN samples were minced immediately after excision and filtered with a 70- $\mu$ m strainer. The cells were washed with phosphate-buffered saline (PBS, Nissui, Tokyo, Japan), containing 0.04% weight/volume bovine serum albumin (BSA, Sigma-Aldrich, Louis, MO, USA), and centrifuged twice for 5 min at 300 × g and 4°C. After removal of the supernatant, cells were resuspended in PBS/0.04% BSA and cell count and viability were estimated using a hemocytometer and trypan blue. After centrifugation for 5 min at 300 × g and 5°C once again, cells were resuspended in PBS/0.04% BSA and diluted to  $1 \times 10^7$  cells/ml in preparation for analysis or cryopreservation.

PB samples were stored at 4°C immediately after collection and processed within 24 h. After red blood cell (RBC) lysis by the ammonium-chloride-potassium buffer, cells were washed once with PBS/0.04% BSA and centrifuged for 5 min at 400 × g and 4°C. After removal of the supernatant, cells were resuspended in 20 ml of PBS/0.04% BSA buffer and cell count and viability were estimated. Cells were centrifuged for 5 min at 300 × g and 4°C, diluted to 1 × 10<sup>7</sup> cells/ml and kept on ice until use.

32

#### 33 FCM analysis and sorting

34 Surface protein expression analysis and sorting for scRNA-seq were performed using cell 35 suspensions obtained from the LN and PB samples described above. To prevent non-specific 36 reactions mediated by Fc receptors (FcRs), 20  $\mu$ /10<sup>7</sup> cells of FcR Blocking Reagent (Miltenvi 37 Biotec, Bergisch Gladbach, Germany) was added, and cell suspensions were incubated in a 38 refrigerator for 10 min, followed by staining based on the recommended concentration of each 39 antibody. Dead cells and doublets were removed by 7-amino-actinomycin D (7-AAD, Thermo 40 Fisher Scientific, Waltham, MA, USA) staining and forward versus side scatter plots (Fig. S1A-41 B). FCM sorting and analysis were performed on BD FACSAria III (BD Biosciences, San Jose, CA, USA). FlowJo software (v10.7.1, Tree Star Inc., Ashland, OR, USA) and the Ggplot2 42 package (v3.3.3) [2] were used for FCM data analysis and visualization. All antibodies used are 43 listed in Table S20. 44

45

## Library preparation, sequencing, and pre-processing of single-cell data

47	The scRNA-seq libraries for mononuclear cells (MNCs) from LNs and PB were prepared
48	using a Chromium Single Cell 5' Library & Gel Bead Kit (v1 chemistry, 10x Genomics,
49	Pleasanton, CA, USA) or a Chromium Next GEM Single Cell 5' Library & Gel Bead Kit (v1.1
50	chemistry) according to the manufacturer's instructions (CG000086 Rev L or CG000207 Rev
51	E), aiming for 5 000 cells per library. Simultaneously, single-cell T- and B-cell receptor
52	sequencing (scTCR/BCR-seq) was performed for samples with sufficient T or B cells (> 20% of
53	all LN MNCs or > 10% of all PB MNCs; Table S1 and S4). scTCR/BCR-seq libraries were
54	constructed using a Chromium Single Cell V(D)J Reagent Kit (v1 or v1.1 chemistry). T cell-
55	enriched scRNA/TCR-seq libraries were generated similarly to the MNCs using sorted
56	CD4/CD8 <sup>+</sup> T cells. Quantification and quality control of libraries were performed using a 2100
57	Bioanalyzer System with High Sensitivity DNA Kit (Agilent Technologies, Santa Clara, CA,
58	USA) and a KAPA Library Quantification Kit for Illumina platforms (KAPA Biosystems,
59	Wilmington, MA, USA). Each cDNA library was sequenced on the HiSeq X system (Illumina,
60	San Diego, CA, USA) with a paired-end 150-base read option. The publicly available 5'
61	scRNA-seq and scTCR/BCR-seq data from PB of 5 healthy donors (HDs) [3] generated by a
62	Chromium system (Chromium Single Cell 5' Reagent Kit v2 chemistry and Chromium Single
63	Cell V(D)J Reagent Kit) were used as controls (Table S1). The age and sex of individual donors
64	were obtained from Supplementary Figure S1 of the original paper [3].
65	Using the "cellranger count" function of the Cell Ranger pipeline (v3.1.0, 10x
66	Genomics), we aligned scRNA-seq data to the reference genome (GRCh38) and performed
67	preliminary filtering and counting unique molecular identifiers (UMIs) for downstream analysis.
68	For scTCR/BCR-seq data, sequence assembly and paired clonotype calling were performed
69	with the "cellranger vdj" function. scRNA-seq and scTCR/BCR-seq data, after implementing

70

71

the Cell Ranger pipeline, were primarily analyzed using R (v3.6.0, v3.6.2 or v4.0.2) on RStudio (v1.2.1578 or v1.2.5019).

- 72
- 73

### Quality control (QC) of scRNA-seq data

74 First, to remove low-quality cells and genes, only genes expressed by more than three cells and cells expressing over 200 genes were included in further analyses. Next, we applied 75 76 the Scater package (v1.14.6) [4] to filter out outliers from count matrices for each sample. 77 Briefly, we used several common QC metrics to detect outliers: library size, which was defined 78 as the total sum of counts across all relevant features for each cell; the number of expressed 79 features in each cell; and the percentage of reads mapped to mitochondrial transcripts. Outliers 80 were identified based on the median absolute deviation from the median value of each QC 81 metric across all cells. Cells identified as outliers were considered to be low quality and 82 discarded. After excluding mitochondrial and ribosomal genes, the Seurat package (v3.2.3) [5,6] was applied to log-normalize the count data by the default scale factor of 10 000. 83 84 85 Batch effects correction and data integration

86 The mutual nearest neighbors (MNN) batch correction technique in the Batchelor

87 package (v1.2.4) [7] was utilized to remove batch effects between datasets resulting from

88 technical biases and biological differences. Unlike the original method, the

89 "batchelor::fastMNN" function performs principal components analysis (PCA) on the

90 previously selected highly variable features (HVFs) to preemptively reduce the dimensions and

91 speed up MNN identification and correction. For integrating data from LNs of patients with

92 TFHL and HLNs, we used 2 000 HVFs and the first 50 principal components (PCs) for

93	downstream steps. For data from PB, 3 000 HVFs and the first 100 PCs were used instead. In
94	LN data, variable genes of TCR $\alpha\beta$ and immunoglobulins ( <i>TRAV</i> , <i>TRBV</i> , <i>IGHV</i> , <i>IGKV</i> , and
95	IGLV) were removed from the HVF selection to avoid their effect on clustering. We applied the
96	"RunFastMNN" function in the SeuratWrappers package (v0.3.0;
97	https://github.com/satijalab/seurat-wrappers) for running the "fastMNN" function with a Seurat
98	object.
99	
100	Unsupervised clustering and non-linear dimensional reduction
101	Subsequently, we applied Seurat to perform unsupervised graph-based clustering and
102	Uniform Manifold Approximation and Projection (UMAP) visualization using the MNN-
103	corrected components as input. Using the "FindNeighbors" function, a k-nearest neighbor graph
104	was constructed based on the Euclidean distance and a shared nearest neighbor graph was
105	generated by computing the neighborhood overlap between any two cells. Next, the
106	"FindClusters" function was used to identify clusters by the Louvain algorithm (default setting),
107	which was a shared nearest neighbor modularity optimization-based clustering algorithm. For
108	visualization, UMAP transformation was performed using the "RunUMAP" function.
109	

### 110 Finding cluster biomarkers and cell type annotation

To characterize each cluster, we used the "FindMarkers" or "FindAllMarkers" functions in the Seurat package to select upregulated genes in each cluster relative to other clusters. These functions performed the Wilcoxon Rank Sum test between pairs of clusters and a *P*-value adjustment using the Bonferroni correction. Clusters were manually assigned to a cell type by comparing the marker genes of each cluster and known canonical markers. Specifically, we annotated CD3 gene (CD3D, CD3E, and CD247)- and CD4 or CD8 gene (CD8A and CD8B)-

117 positive clusters as "CD4/CD8<sup>+</sup> T cells", *CD79A*-positive clusters as "B cells," and myeloid cell

118 marker (LYZ, CD68, and CST3) [8,9]-positive clusters as "myeloid cells." CD3 gene-positive or

- 119 weakly positive but *CD4* and CD8 gene-negative and natural killer (NK) cell marker (*XCL1*,
- 120 FCGR3A, KLRD1, and KLRF1) [10]- or γδT cell marker (TRDV2, TRGV9, TRDC, TRGC2, and
- 121 TRGCI) [11]-positive clusters were named as "NK cells" (for LNs) or "NK/γδT cells" (for PB
- samples). We also identified a *CD34*-positive "progenitor cell" cluster as a rare cell type (81
- 123 cells in all PB MNCs) in PB. Platelet clusters characterized by PPBP, GP9, and PF4 and RBC
- 124 clusters characterized by *HBB* and *HBA1* were excluded from downstream analyses. For

125 clusters featured by the expression of multiple cell-type marker genes, we used the scDblFinder

126 package (v1.4.0) [12] and confirmed that most cells in these clusters were doublets. These cells

127 were also removed from further analysis.

128 Subsequently, after identifying tumor cells by the method described below, we

subclustered immune cells by major cell types and annotated each cluster based on canonical

130 markers. Results of manual annotations were confirmed by automated annotation by the

131 SingleR package (v1.4.1) [13] with reference to previously published single-cell data.

132

#### 133 Single-cell TCR/BCR repertoire analysis

We identified clonotypes from scTCR/BCR-seq data after running the Cell Ranger pipeline. Clonotypes were identified by sets of cells with unique and "productive" TCRα- and/or β-chains (for B cells, immunoglobulin [Ig] heavy [IgH] chains and two types of light [IgL] chains:  $\kappa$  or  $\lambda$ [IgK or IgL] chains), defined by identical complementarity-determining region 3 (CDR3) sequences. Here, a "productive" sequence refers to an mRNA sequence that could be translated into a functional protein. Those TCR- or Ig-chain sequences judged as productive met the 140 following conditions: were full length (include from the beginning of the V gene to the end of the 141 J gene), started with a start codon, contained no stop codon, were in-frame, contained a CDR3 142 sequence, and matched the structural requirements calculated from the length of the V and J gene 143 regions of the (https://support.10xgenomics.com/single-cellsequence 144 vdj/software/pipelines/3.1/algorithms/annotation). These clonotypes were named clonotype 1, 145 clonotype 2, and so on from the most clonally extended ones for each sample. Generally,  $\alpha\beta T$  and 146 B cells express a pair of functional  $\alpha$ - and  $\beta$ -chains or H- and L-chains but, occasionally, a single 147 cell expresses multiple functional TCR or Ig chains [14–17]. Therefore, we detected up to two 148 productive TCRa- and  $\beta$ -chains (IgH- and L-chains) in each cell. Downstream analysis of 149 scTCR/BCR-seq was performed using the Immunarch package (v0.6.6) [18].

150

#### 151 **Tumor cell detection in TFHL LNs and PB**

152 For LNs, we defined clonotypes that were expressed by over 20 CD4<sup>+</sup> T cells and accounted for over 1.5% of all T cells with TCRs as "major tumor-cell clonotypes" and cells 153 154 with tumor-cell clonotypes as "tumor cells" (Fig. 1C; Table S3). Clonotypes composed only of 155 the TCR  $\alpha$ - and/or  $\beta$ -chains identical to the major tumor-cell clonotypes and expressed by five 156 or more CD4<sup>+</sup> T cells were defined as "minor tumor-cell clonotypes." Cells expressing a minor 157 tumor-cell clonotype were also defined as tumor cells. Major and minor tumor-cell clnotypes 158 with the same TCR chains were grouped together as "tumor-clone subgroups" (Table S3). 159 In nine PB samples, with their paired LNs also subjected to single-cell sequencing, cells 160 harboring identical clonotypes to those of their respective LN tumor cells were defined as tumor 161 cells (Fig. S16A). In the remaining seven PB samples without paired LN single-cell data, 162 clonotypes that were expressed by over 100 cells and accounted for more than 10% of all TCRs 163 were defined as tumor-cell clonotypes. In patients with TFHL with sequential samples (AITL1

and AITL2), cells expressing the clonotypes identical to those of tumor cells of the sequential
sample were defined as tumor cells, even if no clonotype met the definition above (Fig. S16B).

100

#### 167

### Differentially expressed gene (DEG) analysis

We performed DEG analysis using the "FindMarkers" or "FindAllMarkers" functions of 168 169 Seurat. The model-based analysis of single-cell transcriptomics (MAST, v1.12.0) [19] method 170 was mainly used for DEG detection, and P-values were corrected by the Bonferroni method. In 171 addition, the Wilcoxon rank sum test confirmed the DEGs detected by MAST. Genes with an 172 adjusted *P*-value < 0.05 in both tests, with a log fold-change (logFC) of the average expression 173 between the two groups  $\ge 0.15$  (logfc.threshold = 0.15), and expressed by  $\ge 10\%$  of cells in the 174 cluster (min.pct = 0.1) were considered significant. An adjusted *P*-value calculated by MAST 175 was used to create a volcano plot. Metascape [20] and gene set enrichment analysis (GSEA; v4.1.0) [21] were used for gene ontology (GO) and pathway analyses of DEGs in specific 176 177 clusters, respectively.

178

### 179 Gene set variation analysis (GSVA)

The GSVA package (v1.34.0) [22] was applied to estimate signatures or pathways enriched by each cell and cluster. The normalized data after log transformation was used as input, and the Gaussian kernel was selected as the kernel function used for the nonparametric estimation of enrichment scores for each cell. Gene sets for GSVA were downloaded from the Molecular Signatures Database (MSigDB; http://www.gsea-msigdb.org/gsea/msigdb/index.jsp) or extracted from a previously published RNA-seq dataset by DEG analysis using the edgeR package (v3.28.1) [23,24]. We used raw count data as input for DEG analysis by edgeR, filtered

187	out low-expression genes using the "filterByExpr" function, performed trimmed mean of M-
188	values (TMM) normalization using the "calcNormFactors" function, and applied a generalized
189	linear model (GLM) using the likelihood ratio test (LRT) with the "glmLRT" function. DEGs
190	with an adjusted <i>P</i> -value $< 0.05$ and logFC $\ge 1$ were extracted by the "decideTests" function.
191	Finally, we performed the pairwise Wilcoxon test and Bonferroni P-value correction using the
192	rstatix package (v0.7.0) [25] to compare median GSVA enrichment scores for each cluster.
102	

193

#### 194 **Trajectory analysis**

195 Trajectory analysis was performed using the Monocle2 (v2.18.0) [26], Monocle3 196 (v0.2.3.0) [27], and Slingshot (v1.8.0) [28] packages. The count data before normalization after 197 QC was used as the input data for Monocle2. After estimating size factors and dispersions with the "estimateSizeFactors" and "estimateDispersions" functions, DEGs for each cluster were 198 199 extracted with the "differentialGeneTest" function. Using only DEGs with a P-value < 0.01, the 200 "reduceDimension" function performed a DDRTree reduction, and the "orderCells" function 201 sorted the cells in trajectory order. In the Monocle3 analysis, we first converted the Seurat 202 object to a "cell data set" object that could be used in Monocle3 by the "as.cell data set" 203 function. After clustering with the "cluster cells" function, trajectory estimation and cell sorting 204 were performed using the "learn graph" and "orderCells" functions, using the results of 205 dimensional reduction by UMAP executed by Seurat. In trajectory analysis by Slingshot, after converting the Seurat object to a "SingleCellExperiment" object using the 206 "as.SingleCellExperiment" function, dimensionality reduction data after batch effect correction 207 by fastMNN and clustering results by Seurat were used. Trajectory estimation was performed 208 209 by the "slingshot" function. We used the rgl package (v0.107.14, 210 https://github.com/dmurdoch/rgl) for 3D plots.

211

#### 212 Cell-cell interaction analysis

213 Ligand-receptor interactions between each cluster were estimated using the Python 214 package CellPhoneDB (v3.0.0) [29] and the R package NicheNetR (v1.0.0) [30]. We used 215 Python v3.8.5 for this analysis. In the CellPhoneDB analysis, we first performed the "statistical 216 method" and obtained P-values. Specifically, only ligand-receptor pairs expressed by over 10% 217 of the cells in each cluster were selected for analysis. Then, we randomly permuted the cluster 218 labels of all cells 1 000 times to create a null distribution of the mean of the average ligand and 219 receptor expression levels in the interacting clusters. P-values for the probability of enrichment 220 within clusters for each ligand-receptor complex were obtained by calculating the percentage of 221 the means equal to or higher than the actual mean. Subsequently, we performed the "DEGs 222 analysis method," using DEGs upregulated in each cluster of LNs from patients with ND or RR 223 TFHL versus HLNs as the input genes of the DEG list. As for CD8  $T_{DYS}$  (T9), since the number 224 of cells belonging to CD8 T<sub>DYS</sub> of HLNs was too small to perform proper DEG analysis, we 225 compared them with CD8 T<sub>EFF</sub> (T8) of HLNs. Genes whose expression profiles were 226 significantly elevated in the tumor cells versus non-malignant cells were used as the DEGs for 227 the tumor cells. In the "DEGs analysis method," only ligand-receptor pairs expressed by over 228 10% of the cells in each cluster and for which at least one gene was included in the DEG list were extracted as significant interactions. Finally, interactions detected as significant by both 229 230 methods were extracted and the numbers of interactions for each cluster were plotted in 231 heatmaps.

232 NicheNetR is a tool for predicting ligands that can promote gene expression changes in 233 specific target cells ("receiver/target"). In this analysis, the group of genes representing gene 234 expression changes in target cells was defined as a "gene set of interest (geneset oi)." The CD8

11

235	$T_{DYS}$ (T9) cluster and tumor cells from RR TFHL were set as receivers and senders,
236	respectively. Initially, genes expressed by over 10% cells in each cluster designated as a
237	receiver or sender were used as "expressed_genes_receiver" and "expressed_genes_sender,"
238	respectively. Scince the number of cells belonging to CD8 $T_{DYS}$ of HLNs was too small to
239	perform proper DEG analysis, DEGs between CD8 $T_{DYS}$ of RR TFHL LNs and CD8 $T_{EFF}$ (T8)
240	of HLNs with an adjusted <i>P</i> -value < 0.05, min.pct = 0.1, and logFC $\ge$ 0.35 were used as
241	"geneset_oi." Next, we used the "predict_ligand_activities" function to estimate and rank the
242	potential ligands of target genes in "geneset_oi." Among the potential ligands, the top 20 were
243	used as the "best_upstream_ligands" for the following analysis. Furthermore, the
244	"get_weighted_ligand_target_links" and "lr_network" functions predicted target genes and
245	receptors of the "best_upstream_ligands." Finally, only bonafide interactions based on validated
246	curated ligand-receptor databases were visualized in heatmaps.
247	

### 248 Whole-exome sequencing (WES) and data processing

Genomic DNA were extracted from fresh frozen tumor tissue and PB samples, formalin-249 250 fixed paraffin-embedded (FFPE) tumor samples, and paired buccal swab samples to be used as 251 reference using a QIAamp DNA Blood Mini Kit or GeneRead DNA FFPE Kit (Qiagen, Hilden, 252 Germany) (Table S1). After DNA integrity number (DIN) values were measured using Agilent 253 TapeStation 2200 (Agilent Technologies) for quality control, DNA was fragmented with DNA 254 Shearing S220 (Covaris, Woburn, MA, USA). Exome capturing was performed using a 255 SureSelect XT Human All Exon V7 kit (Agilent Technologies). Next, 150-bp paired-end 256 sequencing was carried out according to the manufacturer's recommendations on a HiSeq X 257 Ten system (Illumina).

258	Sequencing reads were aligned to the reference genome (GRCh37) using the Burrows-
259	Wheeler Aligner (v.0.7.8). Mutation calling was performed using the Genomon2 pipeline
260	(v.2.6.2, https://github.com/Genomon-Project) as previously described [1,31,32] with minor
261	modifications. Putative somatic mutations with a Fisher's exact $P$ -value < 0.01 or an EB call $P$ -
262	value > 2.0, sequencing depth $\ge$ 30, and variant reads > 4 were adopted. Furthermore, variants
263	only in unidirectional reads; variants in repetitive genomic regions; variants in intergenic,
264	intronic, untranslated, and noncoding RNA regions; and synonymous single-nucleotide variants
265	were excluded. Additionally, known recurrently mutated genes in TFHL, including RHOA
266	G17V, TET2, DNMT3A, and IDH2, were manually screened for as additional mutations.
267	Mapping errors were excluded by visual inspection with Integrative Genomics Viewer (IGV)
268	[33]. Detected somatic mutations are listed in Table S5.
269	Somatic copy number variations (CNVs) were analyzed by the Genome Analysis Tool Kit
270	(GATK; v4.2, Broad Institute, Cambridge, MA, USA) [34]. Buccal samples were used as a
271	panel of normals. The interval list was generated from the target browser extensible data (BED)
272	file of the SureSelect XT Human All Exon V7 kit downloaded from the Agilent website
273	(https://earray.chem.agilent.com/suredesign/index.htm). Gains and losses less than 1 Mb in
274	length were removed from downstream analyses.
275	
276	Inferring genetic mutations using scRNA-seq data

We applied VarTrix (v1.1.16, 10x Genomics, https://github.com/10XGenomics/vartrix) to extract single-cell variant information from scRNA-seq data. First, BED files of the somatic mutations extracted by the Genomon2 pipeline for WES data were lifted from GRCh37 to GRCh38 with the UCSC web browser (https://genome.ucsc.edu/cgi-bin/hgLiftOver). Then, the BED files converted to variant call format (VCF) were used as input for VarTrix. We ran the

"vartrix" command with --mapq 255, --padding 100, and --umi mode options using a cell barcode 282 283 file extracted from the integrated Seurat object and a binary alignment map (BAM) file generated by the Cell Ranger pipeline for each sample. Briefly, local sequence alignment at the input variant 284 285 locus was performed by the Smith-Waterman algorithm, and then wild-type and mutant reads 286 were counted for each cell, respectively. In --umi mode, a consensus is taken across each UMI, 287 and only cases where each UMI exceeded a hardcoded 90% threshold for supporting the same 288 allele were reflected in the results. Owing to the phenomenon commonly occurring in scRNA-289 seq called "allelic dropout" (insufficient amplification of one allele), it is impossible to judge whether a cell is a "truly wild type (WT)" in the absence of mutant reads [35]. Therefore, we 290 291 defined a cell as "unknown" if only WT reads or no reads were detected. Cells from THFL patients 292 without WES-identified mutations were classified as "WT" cells.

293

#### 294 Estimation of CNVs at the single-cell level

295 To infer large-scale CNVs from scRNA-seq data, we applied the R package inferCNV 296 (v1.10.1). [36] Non-malignant T cells from each sample were used as controls for analysis of 297 PB and LN tumor cells. We used the following parameters: default de-noise and hidden Markov 298 model (HMM) setting, cutoff = 0.1, cluster by groups = FALSE, analysis mode =299 'subclusters', and tumor subcluster partition method = 'random trees'. Specifically, after 300 removeing noise with the default settings, the random trees method was used to divide cells into 301 groups with consistent CNV patterns, and CNV prediction by HMM was performed at the 302 subcluster level. Uphyloplot2 (v2.3) [37] was applied to visualize phylogenetic trees using the inferCNV output of each sample. CNV scores for each cell were calculated as previously 303 304 described [38].

305

#### 306 Immunohistochemical (IHC) staining

307 Regarding PLS3, which was identified as a candidate tumor cell-specific gene, IHC 308 staining using FFPE samples of tumor tissues was performed by either the Tsukuba Human 309 Tissue Biobank Center Tsukuba Pathological Analysis Support Service (T-PASS, Tsukuba, 310 Japan) or expert hematopathologists at Tokai University School of Medicine. After antigen 311 retrieval with Target Retrieval Solution pH 9.0 (Dako, Santa Clara, CA, USA) using the 312 automated pretreatment system PT Link (Dako; 97°C, 20 min), anti-PLS3 antibody (Sigma-313 Aldrich) diluted 1:100 was added, and samples were stained with Autostainer Link 48 (Dako). 314 PLS3 staining was determined to be positive when 10% or more of the cells were positive. 315 316 High-dimensional spatial analysis by imaging mass cytometry (IMC) 317 Carrier-free antibodies were manually conjugated to metal isotopes using the MaxPar 8X 318 antibody labeling kit (Standard BioTools Inc., South San Francisco, CA, USA) following the 319 manufacturer's protocol (Maxpar Antibody Labeling Kit PRD002 Version 11). Manually 320 conjugated or pre-metal-tagged antibodies obtained from Standard BioTools Inc. were used for 321 IMC staining (Table S17). FFPE samples from TFHL tissues were incubated in a dry oven for 322 15 min at 55°C, deparaffinized, and rehydrated using a graded ethanol series. Antigen retrieval 323 was performed using Target Retrieval Solution pH 9.0 (Dako) in a Decloaking Chamber 324 (Biocare Medical, Pacheco, CA, USA) for 10 min at 95°C. Slides were incubated overnight at 325 4°C with a cocktail of metal-conjugated primary antibodies after blocking with buffer 326 containing 3% BSA. The following day, slides were washed twice with Dulbecco's PBS and 327 counterstained using Cell-ID Intercalator-Ir (Standard BioTools Inc.) for 30 min at RT to visualize the DNA. After a final wash in doubly distilled H<sub>2</sub>O, the slides were air-dried for 20 328

329 min. IMC data was acquired using a Hyperion imaging system (Standard BioTools Inc.).

330 Subsequently, five regions of interest (ROIs) of  $1500 \times 1500 \,\mu\text{m}$  per 1 FFPE sample were

331 identified on consecutive Hematoxylin and Eosin (H&E)-stained slides and ablated by the laser

332 beam.

We converted raw data, exported as MCD files, to the OME-TIFF format and segmented into single cells using the ImcSegmentationPipeline [39]. Specifically, we applied Ilastik (v1.3.3) [40] for pixel classification and generated pixel probability maps for three labels ("nucleus," "cytoplasm," and "background"). Then, cells were segmented based on pixel probabilities and single-cell or image features, such as channel intensities and the number of neighbors, were measured using the CellProfiler (v4.2.1) [41].

339 The output data from CellProfiler was imported into R (v4.1.0) as a SpatialExperiment 340 object by the imcRtools package (v1.0.2) [42]. After the inverse hyperbolic sine transformation 341 and normalization at the 99th percentile, batch effect correction and unsupervised clustering 342 were performed using the Batchelor and Seurat packages, like with the scRNA-seq data. When 343 performing clustering, four proteins with poor cell-to-cell variability (CD10, E-cadherin, 344 ICOSL, and CD40LG) and two proteins related to the stromal structures ( $\alpha$ -smooth muscle 345 actin [SMA] and collagen type I) were excluded. By annotation with canonical markers, we 346 identified a T<sub>FH</sub> marker-positive cluster thought to be tumor cells and performed re-clustering 347 with immune and stromal cells other than tumor cells. Next, we computed the averaged cell-cell 348 interaction counts and compared them to a null distribution of counts generated by random permutations to estimate the interaction or avoidance between cell types using the 349 350 "testInteractions" function of imcRtools (Table S19). Finally, the pixel- and cell-level 351 visualization of each image was performed by the cytomapper package (v1.6.0) [43].

352

#### 353 Code Availability

The code used for data analysis are available from the corresponding author upon request (sakatama@md.tsukuba.ac.jp [M.S.-Y.]).

356

#### 357 Supplementary Notes

### 358 Supplementary Note 1: Related to "Expansion of dysfunctional CD8<sup>+</sup> and regulatory T cells

#### 359 in LNs" and "Clonal tracking between T cells in LNs and PB"

The following is a comment regarding subclustering and the TCR analysis of non-malignant PBT cells.

362 Subclustering of non-malignant PB T cells revealed a similar immunophenotype to those 363 of LNs. Specifically, the proportions of CD8 T<sub>DYS</sub> and T<sub>PRO/DYS</sub> were increased, whereas those of

364 CD4/CD8  $T_N$  and  $T_{CM}$  were decreased in patients with TFHL compared with those in HDs (Fig.

365 S10A–B). Although the increase in the proportion of  $T_{REG}$  was not significant, the proportion of

366 proliferating  $T_{REG}$  and the expression levels of  $T_{REG}$  activation markers such as *FOXP3*, *BATF*,

367 TNFRSF4, and TNFRSF18 [44] and co-inhibitory molecules such as PDCD1 and TIGIT were

368 higher in the  $T_{REG}$  of patients with TFHL than those of HDs (Fig. S10C-F).

369 By TCR repertoire analysis of non-malignant T cells in PB, we found that effector CD8<sup>+</sup>

370 T cells (effector memory  $[T_{EM}]$  and effector memory cells re-expressing CD45RA  $[T_{ERMA}]$ ) were

371 clonally expanded in both patients with TFHL and HDs, whereas CD8  $T_{DYS}/T_{PRO/DYS}$  were

- 372 clonally expanded only in the patients with TFHL (Fig. S17A). TCR overlap analysis showed
- 373 that CD8  $T_{DYS}$  and CD8  $T_{PRO/DYS}$  shared their TCRs in TFHL PB while no shared TCRs were
- detected between effector and dysfunctional CD8<sup>+</sup>T cells of TFL PB, unlike the LN data (Fig.
- 375 S17B). In addition, over 50% of known, pathogen-specific CDR3s, such as cytomegalovirus

376 (CMV), Epstein-Barr virus (EBV), and influenza virus detected by collation with VDJdb

377 database [45], were concentrated in effector CD8<sup>+</sup> T cells in both TFHL patients and HDs,

378 suggesting that they were "bystander" CD8<sup>+</sup> T cells that recognized antigens unrelated to tumor

379 cells (data not shown).

380

381 Supplementary Note 2: Related to "In-silico and spatial intercellular interactions and

#### 382 formation of the TFHL immune-evasive microenvironment"

The following is a comment regarding the subclustering and annotation of non-malignant cellsin the spatial analysis.

385 By unsupervised clustering and annotation using canonical markers, we identified 14

 $\label{eq:subclusters:granzyme} 386 \qquad subclusters: granzyme B \, (GZMB)^{low} \, PD1^{high} \, CD8 \, T_{DYS}, \, GZMB^{high} \, PD1^{low} \, CD8 \, T_{EFF},$ 

 $387 \qquad FOXP3/CD25^+ T_{REG}, CD3/CD4^+ \text{ or } CD3/CD8^+ \text{ T cells}, CD19^+ \text{ B cells}, CD3^- CD4^{dim} CD14^+ \text{ or } CD14^+ \text{ or } CD3/CD8^+ \text{ T cells}, CD19^+ \text{ B cells}, CD3^- CD4^{dim} CD14^+ \text{ or } CD14^+ \text{ or } CD3/CD8^+ \text{ T cells}, CD19^+ \text{ B cells}, CD3^- CD4^{dim} CD14^+ \text{ or } CD3/CD8^+ \text{ T cells}, CD19^+ \text{ B cells}, CD3^- CD4^{dim} CD14^+ \text{ or } CD3/CD8^+ \text{ CD3}, CD3^- CD4^{dim} CD14^+ \text{ or } CD3/CD8^+ \text{ CD3}, CD3^- CD4^{dim} CD14^+ \text{ or } CD3/CD8^+ \text{ CD3}, CD3^- CD4^{dim} CD14^+ \text{ or } CD3/CD8^+ \text{ CD3}, CD3^- CD4^{dim} CD14^+ \text{ or } CD3/CD8^+ \text{ CD3}, CD3^- CD4^{dim} CD14^+ \text{ or } CD3/CD8^+ \text{ CD3}, CD3^- CD4^{dim} CD14^+ \text{ or } CD3/CD8^+ \text{ CD3}, CD3^- CD4^{dim} CD14^+ \text{ or } CD3/CD8^+ \text{ CD3}, CD3^- CD4^{dim} CD14^+ \text{ or } CD3/CD8^+ \text{ CD3}, CD3^- CD4^{dim} CD14^+ \text{ or } CD3/CD8^+ \text{ CD3}, CD3^- CD4^{dim} CD14^+ \text{ or } CD3/CD8^+ \text{ CD3}, CD3^- CD4^{dim} CD14^+ \text{ or } CD3/CD8^+ \text{ CD3}, CD3^- CD4^{dim} CD14^+ \text{ or } CD3/CD8^+ \text{ CD3}, CD3^- CD4^{dim} CD14^+ \text{ or } CD3/CD8^+ \text{ CD3}, CD3^- CD4^{dim} CD14^+ \text{ or } CD3/CD8^+ \text{ CD3}, CD3^- CD4^{dim} CD14^+ \text{ or } CD3/CD8^+ \text{ CD3}, CD3^- CD4^{dim} CD14^+ \text{ or } CD3/CD8^+ \text{ CD3}, CD3^- CD4^{dim} CD14^+ \text{ or } CD3/CD8^+ \text{ CD3}, CD3^- CD4^{dim} CD14^+ \text{ or } CD3/CD8^+ \text{ CD3}, CD3^- CD4^+ CD3^- CD4^+ CD3^+ CD3^+ CD3^+ CD3^- CD4^+ CD3^+ CD3^+ CD3^+ CD3^+ CD3$ 

388 myeloid cells, CD3/CD4/CD19<sup>-</sup>CD132/CD11B<sup>+</sup> NK cells, and CD21/CD35<sup>+</sup> follicular

dendritic cells (FDCs) (Table S18). Cluster 10 showed CD20<sup>-</sup> CD19/CD79A<sup>dim</sup>, annotated as

390 PBL/PC (Fig. S18A). Cluster 13 exhibited high expressions of  $\alpha$ -SMA and collagen type I,

- 391 whereas lineage markers were negative (Fig. S18B), suggestive of stromal cells such as
- 392 endothelial cells of blood and lymphatic vessels.


393 Consistent with previous reports on AITL [46], FDCs formed meshwork structures and

- 394 were identified as indistinguishable clusters from surrounding cells (clusters 3, 6, and 11; Fig.
- 395 S18C). Moreover, B cells adjacent to tumor cells were recognized as a single cluster with tumor
- 396 cells (cluster 12; Fig. S18D).

#### **397 Supplementary Table Legends**

- 398 Supplementary Table 1. Characteristics of patients with TFHL and controls and comparison of
- 399 patient cohorts.
- 400 **Supplementary Table 2.** IMC analysis of TFHL tumor tissues.
- 401 Supplementary Table 3. Summary of tumor-cell clonotypes detected by scTCR-seq.
- 402 **Supplementary Table 4.** Proportion of cells detected by scRNA-seq and FCM analysis.
- 403 **Supplementary Table 5.** Somatic mutations detected by WES of 14 patients with TFHL.
- 404 **Supplementary Table 6.** Marker genes for each subcluster of LN and PB tumor cells.
- 405 **Supplementary Table 7.** Somatic mutations detected by reanalysis of scRNA-seq.
- 406 Supplementary Table 8. DEGs upregulated in LN and PB tumor cells compared with all
- 407 MNCs and normal  $T_{FH}$  cells.
- 408 Supplementary Table 9. DEG analysis of three candidate genes for novel tumor cell-specific
- 409 markers compared with all non-malignant MNCs.
- 410 **Supplementary Table 10.** IHC staining of PLS3 on PTCLs and B-cell lymphomas.
- 411 **Supplementary Table 11.** DEGs between T<sub>REG</sub> of RR TFHL LNs and HLNs.
- 412 Supplementary Table 12. DEGs between *FCRL4*<sup>+</sup> MBCs (B2) and *FCRL4*<sup>-</sup> MBCs (B1) of
- 413 LNs.
- 414 Supplementary Table 13. DEGs in *FCRL4*<sup>+</sup> MBCs (B2) of ND or RR TFHL LNs compared
  415 with those of HLNs.
- 416 Supplementary Table 14. AITL B-specific gene set cited from Fujisawa et al. (2022) [1] for
- 417 GSEA.
- 418 Supplementary Table 15. DEGs in *XCL1*<sup>+</sup> NK cells (NK1) of ND TFHL LNs compared with
- 419 those of HLNs.


- 420 Supplementary Table 16. DEGs in *XCL1*<sup>+</sup> NK cells (NK1) of RR TFHL LNs compared with
- 421 those of HLNs.
- 422 **Supplementary Table 17.** Antibodies used for IMC analysis.
- 423 Supplementary Table 18. Markers and annotation of each cluster for subclustering of non-
- 424 malignant cells in IMC analysis.
- 425 **Supplementary Table 19.** Results of spatial interaction analysis.
- 426 Supplementary Table 20. Antibodies used for FCM analysis and IHC staining.



#### 427 Figure S1. Cell-surface protein expression analysis and sorting by flow cytometry (FCM)

(A) Mononuclear cell (MNC) sorting of lymph node (LN) and peripheral blood (PB) samples.
After removing doublets and dead cells by forward versus side scatter plot and 7-AminoActinomycin D (7-AAD) staining, MNCs were sorted, and library construction of single-cell
RNA and T-/B-cell receptor (TCR/BCR) sequencing (scRNA/TCR/BCR-seq) or FCM analysis
were performed. FSC, forward scatter; SSC, side scatter.
(B) CD4/CD8<sup>+</sup> T-cell sorting for T cell-enriched library. For samples in which tumorcontaining CD3<sup>-</sup>CD4<sup>+</sup> cells were detected in the lymphocyte fraction in the initial analysis, CD3<sup>+</sup>

- 435  $CD8^+$  cells and  $CD4^+$  cells were sorted.
- 436 (C) Cytokeratin staining for homeostatic LNs (HLNs). Cytokeratin negativity confirmed the437 absence of tumor-cell contamination.
- 438 (D) Detection of tumor cells by surface antigen. Tumor cells were detected as a PD1<sup>bright</sup>CD4<sup>+</sup>
- 439 T-cell population, as previously reported [47].



#### 440 Figure S2. Subclustering and TCR repertoire analysis of LN samples

(A) Absolute number (top of panels) and proportion (bottom of panels) of cells within all LN
MNCs (left panel) and non-malignant LN MNCs (right panel) for each sample, color-coded by
cell types. B, B cell; CD4/CD8 T, CD4<sup>+</sup> and CD8<sup>+</sup> T cell; Myeloid, myeloid cell; NK, natural
killer cell; ND, newly diagnosed T follicular helper cell lymphoma (TFHL); RR, relapsed or
refractory TFHL; Tumor, tumor cell.

446 (B) Comparison between T cells from scRNA-seq data and TCRs from scTCR-seq data of LN
447 samples.

448 (C) Clone size of TCRs in LNs. The number of cells expressing each clonotype was defined449 as clone size and illustrated for each cell.

450 (D) Pie charts of TCR clonotypes for each sample. Tumor clones are colored.

(E) Sankey plots of each clonotype in cases where the major tumor-cell clonotype was a TCR
with a single chain. The major clonotypes are colored in red and green, showing the CDR3
sequences per TCR chain. "NA" indicates that no TCR chain was detected. NA, not available;
TRA, TCR alpha chain; TRB, TCR beta chain.

(F) Relationship between  $CD3^{-}CD4^{+}$  cells and the expression level of PD1 in each sample.

456 CD3<sup>-</sup> CD4<sup>+</sup> (red) and CD3<sup>+</sup> CD4<sup>+</sup> (grey) populations detected by a CD3 versus CD4 plot (left


457 panel) are plotted separately on a histogram of PD1 expression (right panel). Samples in which


458 CD3<sup>-</sup>CD4<sup>+</sup> cells were detected by FCM analysis of LN samples are shown. sCD3ε, surface CD3ε.


459 (G) FCM plots of CD3 versus CD4 for TFHL patients without single-chain TCR expansion.

460 Since LN samples from AITL10 and AITL11 were not available for detailed FCM analysis, only

461 PB FCM data are shown for these patients.









### 462 Figure S3. Single-cell analysis of PB samples

463	(A) Uniform Manifold Approximation and Projection for Dimension Reduction (UMAP) plots
464	of all PB MNCs from 16 TFHL and 5 healthy donor (HD) PB samples, colored according to cell
465	type (top left). Cells are shown separately for each clinical status (top right and bottom). NK/ $\gamma\delta T$ ,
466	natural-killer and gamma-delta T cell.
467	(B) Absolute number (top of panels) and proportion (bottom of panels) of cells within all PB
468	MNCs (left panel) and non-malignant PB MNCs (right panel) for each sample, color-coded by
469	cell types.
470	(C) Relationship between CD3 <sup>-</sup> CD4 <sup>+</sup> cells and the expression level of PD1 in PB samples.
471	CD3 <sup>-</sup> CD4 <sup>+</sup> (red) and CD3 <sup>+</sup> CD4 <sup>+</sup> (grey) populations detected by a CD3 versus CD4 plot (left

472 panel) are plotted separately on a histogram of PD1 expression (right panel). Samples in which


473 CD3<sup>-</sup>CD4<sup>+</sup> cells were detected by FCM analysis of PB samples are shown.







### 474 Figure S4. Bulk genomic profiling of the 14 TFHL patients


- 475 (A) Recurrent gene mutations detected by whole-exome sequencing (WES). Red squares
- 476 indicate single mutations and black ones indicate multiple mutations.
- 477 (B) Copy number variation (CNV) analysis using WES data from tumor tissue samples.
- 478 Significant CNVs were called by the Genome Analysis Tool Kit [34].







Ε CC C1 C2 C3 AITL1ND AITL1RR AITL2ND AITL2RR AITL2 AITL3 AITL4 AITL5 AITL7 AITL8 AITL9 AITL9 AITL11 AITL12 cells 0.4 0.75 0 cells in tumor þ 0.8 0 0.3 0.2 0.5 2 0 0.5 0 2 h ( Proportion of c 0 Ô 0.24 0 80 6 8 OAITL12 0 R ത് 0 0 C Ż Ŕ Ż Ŕ Ż Ë Z B Ż Ë













D cell-cycle phase →UMAP2 ● G1 ● G2/M ● S Proportion of cells 0 50 1 →UMAP1 Ċ0 C1 C2 Ċ3 C4









0

#### 479 Figure S5. Subclustering of tumor cells from LN and PB samples

480 (A) UMAP plots of LN and PB tumor cell subclusters. Cells are color-coded by each sample481 and shown separately for each tissue.

482 (B) Absolute number (top) and proportion within all tumor cells (bottom) of cells for each483 sample, color-coded by tumor subclusters.

484 (C) Heatmap of the top 50 differentially expressed genes (DEGs) for each subcluster. T
 485 follicular helper (T<sub>FH</sub>) markers are shown in red.

(D) Feature plot showing estimation of cell cycle phase. Cell cycle score calculations were
 performed based on canonical markers using the "CellCycleScoring" function of Seurat, and each
 cell is colored according to the estimated cell cycle phase.

(E) Comparison of the proportion of each cluster in LN and PB tumor cells. The boxplots show
the median (center line), interquartile range (box limits), minimum to max values (whiskers), and

491 samples (dots) for each group. *P*-values are shown only when there is a significant difference.

492 (F) Volcano plot of DEGs between LN (pink) and PB (blue) tumor cells. NS, not significant;
493 vs., versus.

494 (G) Comparison of gene set variation analysis (GSVA) enrichment score for T<sub>FH</sub> signature in
495 LN (pink) and PB (blue) tumor cells. The boxplots show the median (center line), mean (center
496 dot), interquartile range (box limits), and minimum to max values (whiskers) for each group.

497 (H) Comparison of PD1 expression levels by FCM in LN (pink) and PB (blue) tumor cells.

498 Tumor cells were detected as a PD1<sup>bright</sup> CD4<sup>+</sup> T cell population by FCM [47]. The boxplots show


499 the median (center line), mean (center dot), interquartile range (box limits), and minimum to max

500 values (whiskers) for each group. MFI, median fluorescence intensity.

(I) t-Distributed Stochastic Neighbor Embedding (t-SNE) plots of FCM analysis for tumor
 cells of AITL8LN (top) and AITL8PB (bottom), colored by the expression levels of T<sub>FH</sub> markers


30


- 503 (PD1, CD10, and CXCR5).
- 504 (J) Trajectory analysis by Monocle3 [27] for LN (top) and PB (bottom) tumor cells. The red
- 505 points were set as the origins of trajectory.
- 506 (K) UMAP plot showing tumor cells with paired-chain (green) and single-chain (orange) TCRs
- 507 (top) and their proportions in each cluster (bottom).
- 508 (L) Heatmap of gene ontology (GO) analysis of tumor cells with paired-chain (green) and
- 509 single-chain (orange) TCRs.
- 510  $*P < 5.0 \times 10^{-2}, ***P < 1.0 \times 10^{-3}, ****P < 1.0 \times 10^{-4}.$





B RHOA G17V ATL5LN/PB ATL5LN/PB ATL5LN/PB ATL5LN/PB ATL5LN/PB ATL5LN/PB ATL11N/PB ATTL1N/PB ATTLNN/PB ATTLNN/P

C LRRC41 (AITL4LN/PB) KRAS L23R (AITL7LN) UMAP1 KRAS L23R (AITL7LN) LCK (AITL8LN) CTNNB1 (AITL8LN) CTNNB1 (AITL8LN) PSMB3 (PTCL1LN) PSMB3 (PTCL1LN) FING1 (PTCL1LN) FING1 (PTCL1LN) O UMAP1 CTNNB1 (AITL8LN) FSMB3 (PTCL1LN) FING1 (PTCL1LN) FING1 (PTCL1LN) O UMAP1 CTNNB1 (AITL8LN) FSMB3 (PTCL1LN) FING1 (PTCL1LN) FING1 (PTCL1LN) O UMAP1 CTNNB1 (AITL8LN) FSMB3 (PTCL1LN) FSMB3 (PTCL1LN)










1 2 tumor-clone of AITL4
 other samples

#### 511 Figure S6. Estimation of genetic mutations using single-cell data

- 512 (A) Overview of reanalysis of somatic mutations using scRNA-seq data.
- 513 (B) Distribution of *RHOA* G17V (G17V) for each sample in LN and PB tumor cells. MUT,
- 514 mutant cells; Unknown, cells with no mutant reads or no coverage.
- 515 (C) Distribution of detectable mutations other than G17V (LRRC41, KRAS L23R, LCK,
- 516 CTNNB1, PSMB3, and RING) in LN and PB tumor cells. The sample names in parentheses show
- 517 the samples in which the mutations were detected. WT, wild-type cells.
- 518 (D) Volcano plot of DEGs between G17V mutant (red) and WT (blue) cells in LN and PB
- tumor cells. G17V unknown cells were removed from the analysis.
- 520 (E) Heatmap of GO analysis of G17V mutant (red) and WT (white) tumor cells.
- 521 (F) Relationship between *LRRC41* mutant cells and their clonotypes in AITL4LN/PB tumor
- 522 cells. In the Sankey plot, tumor clones of AITL4 and *LRRC41* mutant cells (green) are colored.
- 523 (G) UMAP plot showing the distribution of AITL4 tumor clones.



Modified expression 1.1 1.05 1 0.95 0.9 Tumor-clone subgroup

Cluster

Cluste C0 C1 C2 C3 C3 C4

CNV subgroup

A BC DE FG H

0.5

-0.5

0

\*\*\*\*

C2

AITL10LN

chr5 gain No chr5 gain

\*\*\*\*

C3

\*\*\*\*

C4

#### 524 Figure S7. Inferring CNVs using single-cell data

(A) Heatmaps of estimated CNVs for LN tumor cells by inferCNV [36]. Right bars represent
 tumor clones, subclusters of tumor cells, and subgroups based on CNV patterns, respectively. chr,
 chromosome.

- 528 (B) Volcano plot of DEGs between tumor cells with chr5 gain (red) and those without (blue).
- 529 (C) Comparison of GSVA enrichment score for the  $T_{FH}$  signature between tumor cells with

530 chr5 gain (pink) and those without (blue) in TFHL LNs with partial chr5 gain.


- 531 (D) Heatmaps of estimated CNVs for PB tumor cells in AITL10 and AITL12.
- 532 (E) Distribution (left) and comparison for each cluster (top right) or tissue (bottom right) of

533 CNV scores estimated using scRNA-seq data. In the boxplots of the top right panel, the dotted

534 line represents the mean CNV scores across all clusters and adjusted *P*-values are calculated by


535 the pairwise Wilcoxon test for each cluster against the mean value of all clusters.

- 536 All boxplots show the median (center line), mean (center dot), interquartile range (box limits),
- and minimum to max values (whiskers) for each group.  $**P < 1.0 \times 10^{-2}$ ,  $****P < 1.0 \times 10^{-4}$ .



# 538 Figure S8. Identification of novel tumor-specific cell markers

539 (A) Feature plots of candidate marker genes in all LN (top) and PB (bottom) MNCs.



#### 540 Figure S9. Annotation of subclusters of non-malignant LN T cells

541	(A) Proportion of each cluster within non-malignant MNCs (top) and within non-malignant T
542	cells (bottom) for each sample. $T_{CM}$ , central memory T cell; $T_{DYS}$ , dysfunctional T cell; $T_{EFF}$ ,
543	effector T cell; T <sub>N</sub> , naïve T cell; T <sub>PRO</sub> , proliferative T cell; T <sub>PRO/DYS</sub> , proliferative dysfunctional T
544	cell; T <sub>REG</sub> , regulatory T cell.
545	(B) Heatmap of the top 20 DEGs for each cluster of non-malignant LN T cells.
546	(C) Average expression per cluster of selected markers for cell-type annotation in non-
547	malignant LN T cells.
548	(D) Feature plots of dysfunctional T-cell markers.
549	(E) Feature plots of $T_{REG}$ markers.
550	(F) Subclustering of the CD4 $T_{PRO}$ (T5) cluster. UMAP plot (top) and feature plots of $T_{REG}$ and
551	T <sub>FH</sub> markers (bottom).
552	(G) Cell-type estimation scores by SingleR [13] using previously published single-cell data as
553	a reference [48] for each subcluster of non-malignant T cells.


554 (H) Comparison of proportions of each subcluster of CD4 T<sub>PRO</sub> in non-malignant MNCs of

555 each sample. The boxplots show the median (center line), interquartile range (box limits),

556 minimum to max values (whiskers), and samples (dots) for each group. *P*-values are shown only

557 for significant differences. \* $P < 5.0 \times 10^{-2}$ , \*\* $P < 1.0 \times 10^{-2}$ .

558 (I) Volcano plot of DEGs in T<sub>REG</sub> from RR TFHL LNs (red) and those from HLNs (blue).



# Figure S10. Subclustering of non-malignant PB T cells and non-malignant TCR repertoire analysis

561 (A) UMAP plot of non-malignant PB T-cell subclusters. MAIT/γδT, mixture of mucosal-

associated invariant T cells and gamma-delta T cells;  $T_{EM}$ , effector memory T cell;  $T_{EMRA}$ , effector

563 memory T cells re-expressing CD45RA;  $T_{N/CM}$ , mixture of naïve T cells and memory T cells.

564 (B) Comparison of proportions of each cluster in non-malignant MNCs of each sample. P-

565 values are shown only for significant differences.

(C,D) Subclustering of CD4 T<sub>PRO</sub> (T5) cluster from non-malignant PB T cells. UMAP plot (C)
 and expression levels of *FOXP3* and *PDCD1* (D).

- 568 (E) Comparison of proportions of each T5 subcluster in non-malignant MNCs of each sample.
- 569 *P*-values are shown only for significant differences.

570 (F) Volcano plot of DEGs between PB  $T_{REG}$  of TFHL patients and those of HDs.

571 (G) Clone size of TCRs in non-malignant LN T cells. The proportion of each clonotype in all

572 TCRs of non-malignant T cells was calculated for each sample and shown separately for each

573 cluster. Non-expanded, clonotypes were expressed in < 2 cells.

574 (H) Trajectory analysis by Monocle3 [27] for non-malignant LN T cells. The red and blue


575 points were set as the origin of CD4<sup>+</sup> and CD8<sup>+</sup> T cells, respectively.

576 (I) TCR overlap analysis between LN (pink) and PB (blue) non-malignant T cells of TFHL

577 patients.

- 578 All boxplots show the median (center line), interquartile range (box limits), minimum to max
- 579 values (whiskers), and samples (dots) for each group.  $*P < 5.0 \times 10^{-2}$ .

Supplementary Figure 11



low

→UMAP1


#### 580 Figure S11. Annotation of LN myeloid-cell subclusters

- 581 (A) Proportions of each LN myeloid-cell subcluster within non-malignant MNCs (top) and myeloid cells (bottom) for each sample. C1Q+ Mo, complement component C1q positive 582 macrophage; CD1C<sup>+</sup> cDC2, CD1C-positive type2 conventional dendritic cell; Class Mono, 583 classical monocyte; CLEC9A<sup>+</sup> cDC1, CLEC9A-positive type1 cDC; Inter Mono, intermediate 584 monocyte; LAMP3<sup>+</sup> cDC, LAMP3-positive cDC; pDC, plasmacytoid DC. 585 586 (B) Heatmap of the top 20 DEGs for each cluster of LN myeloid cells. (C) Average expression per cluster of selected markers for cell-type annotation in LN myeloid 587 588 cells. 589 (D) Cell-type estimation scores by SingleR [13] for each cluster of LN myeloid cells using scRNA-seq data from Cheng et al. [9] (left) and Villani et al. [5] (right). 590 591 (E) Trajectory inference by Slingshot [28] for LN monocytes and macrophages (M0-2) of 592 TFHL, color-coded by cluster (left) and pseudo-time (right). 593 (F) GSVA enrichment scores for "mature DC enriched in immunoregulatory molecules
- 594 (mregDC)" signature [49] in LN myeloid cells.
- 595 (G) Estimation of the origin of *LAMP3*<sup>+</sup> cDCs of TFHL using a previously reported scoring
  596 system [9,49].
- 597 (H) Violin plots of the top 3 DEGs upregulated in myeloid subclusters increasing in RR TFHL
- 598 LNs compared with those of HLNs. *P*-values are shown only for significant differences. \*P < 5.0

599 
$$\times 10^{-2}$$
, \*\* $P < 1.0 \times 10^{-2}$ , \*\*\* $P < 1.0 \times 10^{-3}$ , \*\*\*\* $P < 1.0 \times 10^{-4}$ .

600 (I) Feature plot of *CCL17* in LN myeloid cells from TFHL patients.

Supplementary Figure 12



# 601 Figure S12. Annotation of LN B-cell subclusters

602	(A) Proportions of each LN B-cell subcluster within non-malignant MNCs (top) and within B
603	cells (bottom) for each sample. FCRL4 <sup>+</sup> MBC, FCRL4-positive memory B cell; GCB (DZ),
604	germinal center B cell in the dark zone; GCB (LZ), GCB in the light zone; MBC, memory B cell;
605	NBC, naïve B cell; PBL, plasmablast; PC, plasma cell; preGCB, pre-germinal center B cell.
606	(B) Heatmap of the top 25 DEGs for each cluster of LN B cells.
607	(C) Average expression per cluster of selected markers for cell-type annotation in LN B cells.
608	(D) Volcano plot of DEGs in FCRL4 <sup>+</sup> MBCs (B2, red) and FCRL4 <sup>-</sup> MBCs (B1, blue) of LNs.
609	(E) Volcano plot of DEGs in FCRL4 <sup>+</sup> MBCs from RR TFHL LNs (red) and those from HLNs
610	(blue).
611	(F) Dot plot of GO analysis of DEGs upregulated in B cells from TFHL LNs compared with
612	those from HLNs for GCB-related pathways analyzed by Fujisawa et al. [1].
613	(G) Dot plot of gene set enrichment analysis for an AITL B-specific gene set previously
614	reported [1]. Cut-off, false discovery rate (FDR) $q$ -value < 0.25; NSE, normalized enrichment
615	score.
616	(H) Pie charts of BCR clonotypes for each TFHL sample. The top 10 BCRs are colored and
617	the proportions of the top 5 BCRs are shown.
618	(I) Clone sizes of the top 10 BCR clonotypes for each LN sample. The number (top) and
619	proportions (bottom) of cells expressing each clonotype were shown color-coded by cell types.
620	(J) Trajectory analysis by Monocle3 [27] for the cells sharing BCRs with FCRL4 <sup>+</sup> MBCs in
621	AITL9LN. The red point was set as the origin of the trajectory. The cells without sharing the


622 BCRs are shown in gray.


Supplementary Figure 13 Α В С D LN NK cells MKI67 NK0 NK1 NK2 80.08 0.06 0.04 0.02 0 0 Proportion of cells NKO NKO. NKPRO NK1. XCL1<sup>+</sup> NK NK2. FCGR3A<sup>+</sup> NK NK1 GZMK XCL1 XCL2 ↓ UMAP2 KLRC1 cells XCL1 NK2 1 n = 1 307 cells Proportion of cells in NK 0.75 0 800 Number of cells UMAP1 exeb: 0.5 NK0. NKPRO
 NK1. XCL1<sup>+</sup> NK
 NK2. FCGR3A<sup>+</sup> NK 0.25 0 G FCGR3A high Expression low Expression ND RR HLN -1 -0.5 0 0.5 1 **⊁**UMAP2 F XCL1+ NK (NK1) Ε Proportion of cells in non-malignant cells 0.05 0,1 0.15 TEHLHLN >UMAP1 TFHL ]\* • NK0. NKPRO -Log10(P) HLN Cytokine signaling in immune system ≥15 Regulation of lymphocyte activation G 0.06 RR TFHL LNs vs. HLNs 0.03 10 Lymphocyte mediated immunity TFHL *XCL1*<sup>+</sup> NK 60 (NK1) NK1. XCL1+ NK HALLMARK ALLOGRAFT REJECTION 5 GZMB HLN A . -Log10 (adjusted P value) Cellular response to cytokine stimulus 0 TYROB 0.025 0.05 HALLMARK IL2 STAT5 SIGNALING GZMA TFHL HALLMARK INTERFERON GAMMA RESPONSE KLR<sub>B</sub>1 . ] 40 NK2. FCGR3A<sup>+</sup> NK HLN Regulation of hemopoiesis ĢZMH KLRC3 Regulation of immune effector process AITL5LN ●AITL9LN ●AITL12LN
 ●AITL7LN ●AITL12LN
 ●AITL7LN ●AITL10LN ●PTCL1LN
 ●AITL8LN ●AITL11LN ●HLNs 2/LAGLS3 20 PCP/CE pathway Leukocyte activation IL7R′ Neutrophil degranulation HALLMARK TNFA SIGNALING VIA NFKB 0 HLA-DRA NFKBIA 0 Log<sub>2</sub>FC -2 -1 1 2 Regulation of defense response HALLMARK KRAS SIGNALING UP Up in RR TFHL LNs Positive regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay


Response to peptide


#### 623 Figure S13. Subclustering of LN NK cells

- 624 (A) UMAP plot of LN NK-cell subclusters. *FCGR3A*<sup>+</sup> NK, *FCGR3A*-positive activated natural
- 625 killer cell; NK<sub>PRO</sub>, proliferative NK; *XCL1*<sup>+</sup> NK, *XCL1*-positive tissue-resident NK.
- 626 (B) Proportions of each LN NK-cell subcluster within non-malignant MNCs (top) and within
- 627 NK cells (bottom) for each sample.
- 628 (C) Heatmap of the top 50 DEGs for each cluster of LN NK cells.
- 629 (D) Feature plots of marker genes in LN NK cells.
- 630 (E) Comparison of proportions of each subcluster of LN NK cells in non-malignant MNCs of
- 631 each sample. The boxplots show the median (center line), interquartile range (box limits),
- 632 minimum to max values (whiskers), and samples (dots) for each group. *P*-values are shown only
- 633 when there is a significant difference. \* $P < 5.0 \times 10^{-2}$ .
- (F) Heatmap of the top 10 pathways detected by GO analysis between *XCL1*<sup>+</sup> NKs (NK1) from
- 635 TFHL LNs and those from HLNs.
- 636 (G) Volcano plot of DEGs in *XCL1*<sup>+</sup> NKs (NK1) from RR TFHL LNs (red) and those from
- 637 HLNs (blue).










#### 638 Figure S14. In silico cell-cell interaction analysis of TFHL LNs


- 639 (A) Number of significant interactions detected by *in silico* cellular interaction analysis using
- 640 CellPhoneDB [29] performed between tumor cells and subclusters of immune cells from ND (left)
- 641 and RR (right) TFHL LNs.
- 642 (B,C) Estimation of possible ligands (B), which can cause dysfunctional/exhausted signatures
- 643 of CD8 T<sub>DYS</sub> from RR TFHL LNs, and their receptors expressed on tumor cells (C) by NicheNetR
- 644 [30]. Only interactions selected based on validated curated ligand-receptor databases are
- 645 visualized.
- 646 (D) Dot plot of average expression per tumor-cell subcluster of the receptors that can drive the
- 647 CD8 T<sub>DYS</sub> signature estimated by NicheNetR.

Supplementary Figure 15




#### 648 Figure S15. Single-cell spatial analysis of TFHL tissues

- (A) Feature plots of  $T_{FH}$  markers in all cells from TFHL tissues.
- (B) Proportions of each cluster within all cells (left) and within non-malignant cells (right) for
- 651 each sample.
- 652 (C) Feature plots of markers related to CD8<sup>+</sup>T cell types in non-malignant cells.
- (D) Heatmap of markers for each cluster of non-malignant cells.



#### 654 Figure S16. TCR repertoire analysis of PB samples


- 655 (A) Pie charts of TCR clonotypes for each sample. Tumor clones are colored. Major tumor-
- 656 cell clonotypes are indicated by solid lines, and minor tumor-cell clonotypes are indicated by
- dotted lines. Clonotypes with only one TCR chain are indicated by an asterisk (\*).
- (B) Sankey plots showing TCR tracking of sequential samples (AITL1 and AITL2). The top
- 659 10 clonotypes of samples from ND (AITL1<sub>ND</sub> and AITL2<sub>ND</sub>) and RR (AITL1<sub>RR</sub> and AITL2<sub>RR</sub>)
- 660 TFHLs were compared and CDR3 sequences of each clonotype are shown. The major clonotypes
- 661 of tumor cells are indicated by an asterisk (\*).




### 662 Figure S17. Characteristics of subclusters of non-malignant PB T cells

- 663 (A) Clone size of TCRs in non-malignant PB T cells. The number of cells expressing each
- clonotype was defined as clone size and illustrated for each cell.
- (B) TCR overlap analysis of non-malignant PB T cells, analyzed and illustrated for PB from
- 666 TFHL patients (upper right) and HDs (lower left), respectively.


Supplementary Figure 18







Cluster 3. CD8 T + FDC (P8 ROI2)

С








Cluster 11. B + FDC (P5 ROI5)

Cluster 12. B + Tumor (P2 ROI4)





PD1/CD19/CI

#### 667 Figure S18. Annotation of subclusters of non-malignant cells in spatial analysis

- 668 (A) Violin plots of B-cell markers in B-cell clusters (clusters 9–12).
- (B) Violin plots of stromal and lineage markers in a stromal-cell cluster (cluster 13).
- 670 (C) Representative IMC images of doublet clusters of FDCs and CD8<sup>+</sup>T (cluster 3, left), CD4<sup>+</sup>
- 671 T (cluster 6, middle), and B (cluster 11, right) cells, colored according to expression levels of
- 672 markers for FDCs (CD21 and CD35) and each cell (CD8A, CD4, and CD19, respectively). Cells
- belonging to each doublet cluster are outlined with white lines. ROI, region of interest; Scale bar,
- 674 300 μm (top) and 100 μm (bottom).
- (D) Representative IMC images of doublet clusters of B and tumor cells (cluster 12) colored
- according to expression levels of markers for B cells (CD19), tumor cells (PD1), and FDCs
- 677 (CD21). Cells belonging to each doublet cluster are outlined with white lines. Scale bar,  $300 \,\mu m$
- 678 (left) and 100 μm (right).

# 679 Supplementary References

680	1	Fujisawa M, Nguyen TB, Abe Y, Suehara Y, Fukumoto K, Suma S et al. Clonal
681		germinal center B cells function as a niche for T-cell lymphoma. <i>Blood</i> 2022; 140:
682		1937–1950.
683	2	Wickham H. ggplot2. Springer International Publishing: Cham, 2016 doi:10.1007/978-3-
684		319-24277-4.
685	3	Wen W, Su W, Tang H, Le W, Zhang X, Zheng Y et al. Immune cell profiling of
686		COVID-19 patients in the recovery stage by single-cell sequencing. Cell Discov 2020; 6:
687		31.
688	4	McCarthy DJ, Campbell KR, Lun ATL, Wills QF. Scater: pre-processing, quality
689		control, normalization and visualization of single-cell RNA-seq data in R.
690		<i>Bioinformatics</i> 2017; <b>33</b> : 1179–1186.
691	5	Villani A-C, Satija R, Reynolds G, Sarkizova S, Shekhar K, Fletcher J et al. Single-cell
692		RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors.
693		Science 2017; <b>356</b> . doi:10.1126/science.aah4573.
694	6	Stuart T, Butler A, Hoffman P, Hafemeister C, Papalexi E, Mauck WM et al.
695		Comprehensive Integration of Single-Cell Data. Cell 2019; 177: 1888-1902.e21.
696	7	Haghverdi L, Lun ATL, Morgan MD, Marioni JC. Batch effects in single-cell RNA-
697		sequencing data are corrected by matching mutual nearest neighbors. Nat Biotechnol
698		2018; <b>36</b> : 421–427.
699	8	Lavin Y, Kobayashi S, Leader A, Amir E-AD, Elefant N, Bigenwald C et al. Innate
700		Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses. Cell
701		2017; <b>169</b> : 750-765.e17.
702	9	Cheng S, Li Z, Gao R, Xing B, Gao Y, Yang Y et al. A pan-cancer single-cell

703		transcriptional atlas of tumor infiltrating myeloid cells. <i>Cell</i> 2021; <b>184</b> : 792-809.e23.
704	10	Yang C, Siebert JR, Burns R, Gerbec ZJ, Bonacci B, Rymaszewski A et al.
705		Heterogeneity of human bone marrow and blood natural killer cells defined by single-
706		cell transcriptome. Nat Commun 2019; 10: 3931.
707	11	Pizzolato G, Kaminski H, Tosolini M, Franchini D-M, Pont F, Martins F et al. Single-
708		cell RNA sequencing unveils the shared and the distinct cytotoxic hallmarks of human
709		TCRVδ1 and TCRVδ2 γδ T lymphocytes. Proc Natl Acad Sci USA 2019; 116: 11906–
710		11915.
711	12	Germain P-L, Lun A, Garcia Meixide C, Macnair W, Robinson MD. Doublet
712		identification in single-cell sequencing data using scDblFinder. F1000Research 2021;
713		<b>10</b> : 979.
714	13	Aran D, Looney AP, Liu L, Wu E, Fong V, Hsu A et al. Reference-based analysis of
715		lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat Immunol
716		2019; <b>20</b> : 163–172.
717	14	Padovan E, Casorati G, Dellabona P, Meyer S, Brockhaus M, Lanzavecchia A.
718		Expression of two T cell receptor alpha chains: dual receptor T cells. <i>Science</i> 1993; 262:
719		422–4.
720	15	Schuldt NJ, Binstadt BA. Dual TCR T Cells: Identity Crisis or Multitaskers? J Immunol
721		2019; <b>202</b> : 637–644.
722	16	Shi Z, Zhang Q, Yan H, Yang Y, Wang P, Zhang Y et al. More than one antibody of
723		individual B cells revealed by single-cell immune profiling. Cell Discov 2019; 5: 64.
724	17	Brady BL, Steinel NC, Bassing CH. Antigen receptor allelic exclusion: an update and
725		reappraisal. J Immunol 2010; 185: 3801-8.
726	18	ImmunoMind. immunarch: An R Package for Painless Bioinformatics Analysis of T-Cell

- and B-Cell Immune Repertoires. Zenodo. 2019.
- 728 19 Finak G, McDavid A, Yajima M, Deng J, Gersuk V, Shalek AK et al. MAST: a flexible
- statistical framework for assessing transcriptional changes and characterizing
- heterogeneity in single-cell RNA sequencing data. *Genome Biol* 2015; **16**: 278.
- 731 20 Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O et al.
- Metascape provides a biologist-oriented resource for the analysis of systems-level
  datasets. *Nat Commun* 2019; 10: 1523.
- 21 Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al.
- Gene set enrichment analysis: a knowledge-based approach for interpreting genomewide expression profiles. *Proc Natl Acad Sci U S A* 2005; **102**: 15545–50.
- Hänzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray
  and RNA-seq data. *BMC Bioinformatics* 2013; 14: 7.
- 739 23 Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for
- 740 differential expression analysis of digital gene expression data. *Bioinformatics* 2010; 26:
  741 139–40.
- McCarthy DJ, Chen Y, Smyth GK. Differential expression analysis of multifactor RNASeq experiments with respect to biological variation. *Nucleic Acids Res* 2012; 40: 4288–
- 744
   97.
- Kassambara A. rstatix:Pipe-Friendly Framework for Basic Statistical Tests. R package
  version 0.7.0. *https://CRANR-project.org/package=rstatix* 2021.
- Qiu X, Hill A, Packer J, Lin D, Ma Y-A, Trapnell C. Single-cell mRNA quantification
  and differential analysis with Census. *Nat Methods* 2017; 14: 309–315.
- 749 27 Cao J, Spielmann M, Qiu X, Huang X, Ibrahim DM, Hill AJ et al. The single-cell
- transcriptional landscape of mammalian organogenesis. *Nature* 2019; **566**: 496–502.

751	28	Street K, Risso D, Fletcher RB, Das D, Ngai J, Yosef N et al. Slingshot: cell lineage and
752		pseudotime inference for single-cell transcriptomics. BMC Genomics 2018; 19: 477.
753	29	Garcia-Alonso L, Handfield L-F, Roberts K, Nikolakopoulou K, Fernando RC, Gardner
754		L et al. Mapping the temporal and spatial dynamics of the human endometrium in vivo
755		and in vitro. Nat Genet 2021; 53: 1698–1711.
756	30	Browaeys R, Saelens W, Saeys Y. NicheNet: modeling intercellular communication by
757		linking ligands to target genes. Nat Methods 2020; 17: 159-162.
758	31	Makishima K, Suehara Y, Abe Y, Hattori K, Kusakabe M, Matsuoka R et al. Intratumor
759		heterogeneity of lymphoma identified by multiregion sequencing of autopsy samples.
760		<i>Cancer Sci</i> 2022; <b>113</b> : 362–364.
761	32	Abe Y, Sakata-Yanagimoto M, Fujisawa M, Miyoshi H, Suehara Y, Hattori K et al. A
762		single-cell atlas of non-haematopoietic cells in human lymph nodes and lymphoma
763		reveals a landscape of stromal remodelling. Nat Cell Biol 2022; 24: 565–578.
764	33	Robinson JT, Thorvaldsdóttir H, Winckler W, Guttman M, Lander ES, Getz G et al.
765		Integrative genomics viewer. Nat Biotechnol 2011; 29: 24-6.
766	34	McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A et al. The
767		Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA
768		sequencing data. Genome Res 2010; 20: 1297-303.
769	35	Petti AA, Williams SR, Miller CA, Fiddes IT, Srivatsan SN, Chen DY et al. A general
770		approach for detecting expressed mutations in AML cells using single cell RNA-
771		sequencing. Nat Commun 2019; 10: 3660.
772	36	Tirosh I, Izar B, Prakadan SM, Wadsworth MH, Treacy D, Trombetta JJ et al. Dissecting
773		the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science
774		2016; <b>352</b> : 189–96.

775	37	Kurtenbach S, Cruz AM, Rodriguez DA, Durante MA, Harbour JW. Uphyloplot2:
776		visualizing phylogenetic trees from single-cell RNA-seq data. BMC Genomics 2021; 22:
777		419.
778	38	Peng J, Sun B-F, Chen C-Y, Zhou J-Y, Chen Y-S, Chen H et al. Single-cell RNA-seq
779		highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal
780		adenocarcinoma. Cell Res 2019; 29: 725–738.
781	39	Zanotelli VR, Bodenmiller B. ImcSegmentationPipeline: A pixel-classification based
782		multiplexed image segmentation pipeline. Zenodo 2022. doi:10.5281/zenodo.3841961.
783	40	Berg S, Kutra D, Kroeger T, Straehle CN, Kausler BX, Haubold C et al. ilastik:
784		interactive machine learning for (bio)image analysis. Nat Methods 2019; 16: 1226–1232.
785	41	Stirling DR, Swain-Bowden MJ, Lucas AM, Carpenter AE, Cimini BA, Goodman A.
786		CellProfiler 4: improvements in speed, utility and usability. BMC Bioinformatics 2021;
787		<b>22</b> : 433.
788	42	Windhager J, Bodenmiller B, Eling N. An end-to-end workflow for multiplexed image
789		processing and analysis. <i>bioRxiv</i> 2021.
789 790	43	processing and analysis. <i>bioRxiv</i> 2021. Eling N, Damond N, Hoch T, Bodenmiller B. Cytomapper: an R/bioconductor package
	43	
790	43 44	Eling N, Damond N, Hoch T, Bodenmiller B. Cytomapper: an R/bioconductor package
790 791		Eling N, Damond N, Hoch T, Bodenmiller B. Cytomapper: an R/bioconductor package for visualisation of highly multiplexed imaging data. <i>Bioinformatics</i> 2020; <b>36</b> : 5706–8.
790 791 792		Eling N, Damond N, Hoch T, Bodenmiller B. Cytomapper: an R/bioconductor package for visualisation of highly multiplexed imaging data. <i>Bioinformatics</i> 2020; <b>36</b> : 5706–8. Sakaguchi S, Mikami N, Wing JB, Tanaka A, Ichiyama K, Ohkura N. Regulatory T
790 791 792 793	44	Eling N, Damond N, Hoch T, Bodenmiller B. Cytomapper: an R/bioconductor package for visualisation of highly multiplexed imaging data. <i>Bioinformatics</i> 2020; <b>36</b> : 5706–8. Sakaguchi S, Mikami N, Wing JB, Tanaka A, Ichiyama K, Ohkura N. Regulatory T Cells and Human Disease. <i>Annu Rev Immunol</i> 2020; <b>38</b> : 541–566.
<ol> <li>790</li> <li>791</li> <li>792</li> <li>793</li> <li>794</li> </ol>	44	Eling N, Damond N, Hoch T, Bodenmiller B. Cytomapper: an R/bioconductor package for visualisation of highly multiplexed imaging data. <i>Bioinformatics</i> 2020; <b>36</b> : 5706–8. Sakaguchi S, Mikami N, Wing JB, Tanaka A, Ichiyama K, Ohkura N. Regulatory T Cells and Human Disease. <i>Annu Rev Immunol</i> 2020; <b>38</b> : 541–566. Bagaev D V., Vroomans RMA, Samir J, Stervbo U, Rius C, Dolton G <i>et al.</i> VDJdb in
<ul> <li>790</li> <li>791</li> <li>792</li> <li>793</li> <li>794</li> <li>795</li> </ul>	44	Eling N, Damond N, Hoch T, Bodenmiller B. Cytomapper: an R/bioconductor package for visualisation of highly multiplexed imaging data. <i>Bioinformatics</i> 2020; <b>36</b> : 5706–8. Sakaguchi S, Mikami N, Wing JB, Tanaka A, Ichiyama K, Ohkura N. Regulatory T Cells and Human Disease. <i>Annu Rev Immunol</i> 2020; <b>38</b> : 541–566. Bagaev D V., Vroomans RMA, Samir J, Stervbo U, Rius C, Dolton G <i>et al.</i> VDJdb in 2019: database extension, new analysis infrastructure and a T-cell receptor motif

62

# 799 2016; **127**: 2375–2390.

262.

807

800	47	Yabe M, Gao Q, Ozkaya N, Huet S, Lewis N, Pichardo JD et al. Bright PD-1 expression
801		by flow cytometry is a powerful tool for diagnosis and monitoring of
802		angioimmunoblastic T-cell lymphoma. Blood Cancer J 2020; 10: 32.
803	48	Zhang L, Yu X, Zheng L, Zhang Y, Li Y, Fang Q et al. Lineage tracking reveals
804		dynamic relationships of T cells in colorectal cancer. <i>Nature</i> 2018; 564: 268–272.
805	49	Maier B, Leader AM, Chen ST, Tung N, Chang C, LeBerichel J et al. A conserved
806		dendritic-cell regulatory program limits antitumour immunity. Nature 2020; 580: 257-

63